Orally available agent with therapeutic potential for idiopathic pulmonary fibrosis (IPF; IC50 value 14.44 mM for inhibition of cell proliferation against MRC-5 cells) that has combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Mechanistically, Pirfenidone inhibits not only TGF-β-induced Smad3, p38 and Akt phosphorylation in human lung fibroblasts (HLFs), but also significantly increased RGS2 mRNA and protein expression in fibroblasts.

KEYWORDS: Pirfenidone | supplier | anti-inflammatory | anti-fibrosis agent | AMR-69 | AMR69 | CAS [53179-13-8] | Immunology | idiopathic | pulmonary fibrosis | IPF | antioxidant | antifibrotic | TGF-β | Smad3 | p38 | Akt | RGS2